Laura Housman leads Avalere’s Evidence & Strategy practice, applying her background in evidence generation, commercialization, and strategy to a broad range of client projects.

Before joining Avalere, Laura held a variety of leadership positions in industry and academia, including at Novartis where she led a team in access and health outcomes in support of molecular diagnostics and targeted therapies. Additionally, she founded Access Solutions Consulting, has led a national team in access, outcomes, and population health with Exact Sciences, and developed novel risk-sharing arrangements during her tenure at BlueCross BlueShield of Massachusetts.

Laura has a BA in economics, a Master of Public Health, and a Master of Business Administration from Boston University. She is currently a doctoral candidate in the School of Public Health at Boston University.

Authored Content

In Part 2 of our video series on the negotiated drug list, Avalere experts discuss topics including effectiveness measures that will inform CMS’s maximum fair price determinations, evidence generation strategies for manufacturers with products that have been selected for negotiation, or that are eligible for selection in the future, and CMS’s definition of therapeutic alternatives.

Laura Housman, Avalere’s Evidence and Strategy Practice Director, discusses her past experience, trends in real-world evidence, and the role of data in advocating for the patient voice.

Delve into the far-reaching implications of the recently announced negotiated drug list as Avalere experts provide insights and answers to pressing questions surrounding CMS's landmark decision on Part D drug pricing and its impact on manufacturers, patients, and the future healthcare landscape.

Manufacturers should adjust commercial and evidence generation strategies in response to the shifted incentives under the IRA and Enhancing Oncology Model.

Sponsors with portfolio or pipeline assets within certain therapeutic areas can prepare for the downstream effects of price negotiation on the market.

New quality measures related to continuous glucose monitoring (CGM) were published in The Science of Diabetes Self-Management and Care by iDQI.

Ahead of the Asembia and ISPOR 2023 conferences, Avalere experts discuss the increasing importance of value and evidence strategies as part of Inflation Reduction Act (IRA) implementation planning.

IRA inflation rebates and drug price negotiation will impact drug launch prices in Medicare, with spillover effects in the Medicaid and commercial markets.

As CMS clarifies evidence requirements for drug price negotiations, manufacturers should prepare their strategies for asset development and on-market products.

On March 2, 2023, the Improving Diabetes Quality Initiative (iDQI) hosted a corporate roundtable to discuss the future of diabetes care and technology.

CMMI releases long-awaited response to President Biden’s executive order on drug pricing with a directive for the Centers for Medicare & Medicaid Services (CMS) to develop three models.

Avalere’s white paper draws on recommendations from a multi-stakeholder workshop to look at roadblocks and solutions for scaling sustainable solutions to address the diagnosis of rare disease.